| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
17,824 |
16,031 |
$1.35M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
16,559 |
14,133 |
$1.19M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,120 |
3,412 |
$375K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
4,604 |
4,312 |
$353K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,523 |
2,837 |
$336K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
4,583 |
4,161 |
$334K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
2,826 |
1,698 |
$300K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
4,417 |
3,329 |
$294K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,606 |
1,425 |
$289K |
| 80053 |
Comprehensive metabolic panel |
17,707 |
13,023 |
$254K |
| 81001 |
|
10,133 |
8,653 |
$233K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,659 |
1,434 |
$174K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,009 |
878 |
$174K |
| 36415 |
Collection of venous blood by venipuncture |
6,544 |
4,076 |
$163K |
| G0378 |
Hospital observation service, per hour |
7,051 |
2,564 |
$149K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,855 |
1,293 |
$81K |
| 87400 |
|
1,485 |
1,372 |
$79K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,467 |
1,179 |
$52K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
19,939 |
14,243 |
$50K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,986 |
2,478 |
$48K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
933 |
832 |
$40K |
| 82962 |
|
5,497 |
2,014 |
$34K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,502 |
1,714 |
$30K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
671 |
434 |
$27K |
| 71046 |
Radiologic examination, chest; 2 views |
2,368 |
2,131 |
$26K |
| 71045 |
Radiologic examination, chest; single view |
6,698 |
5,582 |
$26K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
240 |
228 |
$25K |
| A9270 |
Non-covered item or service |
3,893 |
1,729 |
$24K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
617 |
469 |
$23K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,832 |
4,937 |
$21K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
241 |
212 |
$21K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
282 |
89 |
$21K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
2,297 |
1,935 |
$19K |
| 86850 |
|
886 |
736 |
$19K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
6,578 |
4,870 |
$18K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
452 |
417 |
$17K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,751 |
2,054 |
$16K |
| 85610 |
|
7,644 |
6,080 |
$16K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
267 |
243 |
$15K |
| 86140 |
|
1,545 |
1,286 |
$14K |
| 84484 |
|
7,542 |
4,555 |
$13K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
524 |
315 |
$13K |
| 76818 |
|
413 |
310 |
$12K |
| 94761 |
|
2,580 |
1,213 |
$11K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
337 |
299 |
$11K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,241 |
1,036 |
$10K |
| J3490 |
Unclassified drugs |
1,660 |
790 |
$9K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,109 |
1,049 |
$8K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,027 |
3,020 |
$8K |
| 85730 |
|
5,953 |
4,904 |
$7K |
| 96376 |
|
1,761 |
964 |
$7K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,826 |
3,009 |
$7K |
| 81025 |
|
2,827 |
2,534 |
$7K |
| 83880 |
|
2,658 |
2,114 |
$6K |
| 86900 |
|
1,300 |
1,094 |
$6K |
| 84703 |
|
1,833 |
1,658 |
$6K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
132 |
125 |
$6K |
| 83735 |
|
3,926 |
2,592 |
$5K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,852 |
2,981 |
$5K |
| 82550 |
|
442 |
375 |
$4K |
| 94664 |
|
733 |
522 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,493 |
3,858 |
$4K |
| 73564 |
|
230 |
190 |
$4K |
| 83690 |
|
4,960 |
4,213 |
$4K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,870 |
1,550 |
$3K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
12 |
12 |
$3K |
| 73630 |
|
217 |
190 |
$3K |
| 73610 |
|
224 |
195 |
$3K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,075 |
905 |
$3K |
| 86901 |
|
1,248 |
1,055 |
$3K |
| 84702 |
|
1,335 |
1,072 |
$2K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
935 |
619 |
$2K |
| 73030 |
|
144 |
121 |
$2K |
| 87186 |
|
1,338 |
1,138 |
$2K |
| 76801 |
|
404 |
345 |
$2K |
| 73110 |
|
89 |
73 |
$2K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
79 |
27 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
804 |
700 |
$2K |
| 12001 |
|
14 |
12 |
$1K |
| J2770 |
Injection, quinupristin/dalfopristin, 500 mg (150/350) |
168 |
108 |
$1K |
| 85027 |
|
482 |
328 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
320 |
282 |
$1K |
| 74018 |
|
152 |
131 |
$1K |
| 87077 |
|
840 |
707 |
$1K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
728 |
629 |
$1K |
| 84100 |
|
1,071 |
564 |
$1K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
40 |
25 |
$1K |
| 73130 |
|
66 |
52 |
$1K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
16 |
14 |
$969.88 |
| 93017 |
|
28 |
27 |
$968.91 |
| 93971 |
|
40 |
40 |
$932.52 |
| 87807 |
|
510 |
457 |
$929.10 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
77 |
76 |
$687.91 |
| 87040 |
|
1,328 |
843 |
$571.24 |
| 85014 |
|
27 |
26 |
$557.83 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
188 |
145 |
$526.42 |
| 85018 |
|
100 |
81 |
$421.74 |
| 84145 |
|
510 |
434 |
$338.00 |
| 85379 |
|
322 |
255 |
$323.99 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
580 |
485 |
$320.70 |
| 87070 |
|
14 |
12 |
$316.27 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
189 |
170 |
$310.98 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
142 |
121 |
$307.71 |
| 72100 |
|
28 |
27 |
$289.46 |
| 59025 |
Fetal non-stress test |
21 |
17 |
$243.95 |
| 80061 |
Lipid panel |
224 |
185 |
$195.32 |
| 74022 |
|
32 |
25 |
$192.92 |
| J2704 |
Injection, propofol, 10 mg |
311 |
260 |
$171.31 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
175 |
157 |
$164.32 |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
13 |
12 |
$160.00 |
| 73502 |
|
16 |
12 |
$156.74 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
45 |
37 |
$145.12 |
| 83605 |
|
719 |
549 |
$140.66 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
210 |
135 |
$115.30 |
| J2060 |
Injection, lorazepam, 2 mg |
187 |
131 |
$98.63 |
| 82248 |
|
570 |
474 |
$84.94 |
| 82247 |
|
56 |
40 |
$77.50 |
| 80143 |
|
161 |
139 |
$61.50 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
68 |
25 |
$34.73 |
| J3105 |
Injection, terbutaline sulfate, up to 1 mg |
17 |
13 |
$29.02 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
621 |
455 |
$27.86 |
| 84436 |
|
57 |
54 |
$20.19 |
| 90715 |
|
32 |
13 |
$14.32 |
| 87641 |
|
30 |
27 |
$13.92 |
| 87081 |
|
233 |
220 |
$9.42 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
515 |
447 |
$9.16 |
| 82077 |
|
393 |
332 |
$7.79 |
| 84132 |
|
19 |
12 |
$1.48 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
591 |
517 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
264 |
220 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
266 |
213 |
$0.00 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
121 |
120 |
$0.00 |
| 99406 |
|
45 |
42 |
$0.00 |
| 86141 |
|
116 |
92 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
122 |
70 |
$0.00 |
| 84480 |
|
33 |
31 |
$0.00 |
| 94760 |
|
175 |
63 |
$0.00 |
| 82150 |
|
32 |
28 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
13 |
13 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
33 |
28 |
$0.00 |
| C1769 |
Guide wire |
17 |
14 |
$0.00 |
| 85652 |
|
25 |
17 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
84 |
74 |
$0.00 |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
16 |
16 |
$0.00 |
| 80179 |
|
159 |
135 |
$0.00 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
18 |
16 |
$0.00 |
| 96367 |
|
14 |
13 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
14 |
13 |
$0.00 |
| 84550 |
|
12 |
12 |
$0.00 |
| J1644 |
Injection, heparin sodium, per 1000 units |
137 |
57 |
$0.00 |
| 87210 |
|
16 |
15 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
15 |
13 |
$0.00 |